XRTX Overview

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Wall Street analysts forecast XRTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

XORTX Therapeutics Inc revenue for the last quarter amounts to -686.42K USD, increased 3.80

XORTX Therapeutics Inc. EPS for the last quarter amounts to -726384.00 USD, decreased -18.42

XORTX Therapeutics Inc (XRTX) has 2 emplpoyees as of May 12 2026.

Today XRTX has the market capitalization of 4.32M USD.